Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood–Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease

Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single subject brain

Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359

Nonparametric permutation tests for functional neuroimaging: A primer with examples

Nichols, T. E., & Holmes, A. P. (2002) · Human Brain Mapping · doi:10.1002/hbm.1058 · Cited by 6,256

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569

Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078

Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease

Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., & Kuhl, D. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420114 · Cited by 1,802

A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.

(1995) · PubMed Central · doi:10.2967/jnumed.120.252510a · Cited by 996

Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease

Mosconi, L. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1762-7 · Cited by 938

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

Greiner, B., Eichelbaum, M. F., Fritz, P., Kreichgauer, H. P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917

Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer’s Disease

Jin, L., Pan, Y., Tran, N. L. L., Polychronopoulos, L. N., Warrier, A., Brouwer, K. L. R., & Nicolazzo, J. A. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01227 · Cited by 17

Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice

Pyun, J., Koay, H., Runwal, P., Mawal, C., Bush, A. I., Pan, Y., Donnelly, P. S., Short, J. L., & Nicolazzo, J. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082084 · Cited by 16

Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function

Goutal, S., Novell, A., Leterrier, S., Breuil, L., Selingue, E., Gerstenmayer, M., Marie, S., Saubaméa, B., Caillé, F., Langer, O., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.08.012 · Cited by 15

Imaging transporters: Transforming diagnostic and therapeutic development

Mann, A., Han, H., & Eyal, S. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.416 · Cited by 15

Studying the Progression of Amyloid Pathology and Its Therapy Using Translational Longitudinal Model of Accumulation and Distribution of Amyloid Beta

Karelina, T., Demin, O. O., Demin, O. O., Duvvuri, S., & Nicholas, T. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12249 · Cited by 15

Abundance of P -glycoprotein and Breast Cancer Resistance Protein Measured by Targeted Proteomics in Human Epileptogenic Brain Tissue

Mann, A., Billington, S. F., Benifla, M., Nguyen, T. B., Han, H., Bennet-Back, O., Gilboa, T., Blatch, D., Fellig, Y., Volkov, O., et al. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00083 · Cited by 15

In vitro vascular toxicity of tariquidar, a potential tool for in vivo PET studies

Durante, M., Frosini, M., Fusi, F., Neri, A., Sticozzi, C., & Saponara, S. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.07.015 · Cited by 15

Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer’s disease drug candidates

Zhou, W., Hu, X., & Tam, K.-Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-16635-4 · Cited by 16

Therapeutic drugs modulate ATP-Binding cassette transporter-mediated transport of amyloid beta(1–42) in brain microvascular endothelial cells

Shubbar, M. H., & Penny, J. I. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173009 · Cited by 14

Molecular and cellular characteristics of cerebrovascular cell types and their contribution to neurodegenerative diseases

García, F., & Heiman, M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00799-z · Cited by 14

The Ubiquitin E3 Ligase Nedd4 Regulates the Expression and Amyloid-β Peptide Export Activity of P-Glycoprotein

Chai, A. B., Callaghan, R., & Gelissen, I. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031019 · Cited by 15

The relationship among amyloid-β deposition, sphingomyelin level, and the expression and function of P-glycoprotein in Alzheimer’s disease pathological process

Yang, Q., Xing, Z., Du, L., Fang, X., Liang, H., Zhang, S., Shi, L., Kuang, C., & Han, T.-X. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.358607 · Cited by 15

A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease

Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13

Cycloastragenol inhibits Aβ1–42-induced blood-brain barrier disruption and enhances soluble Aβ efflux in vitro

Huang, M.-Y., & Yu, G. (2020) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2020.1786372 · Cited by 13

Voxel-based morphometry reveals the correlation between gray matter volume and serum P-tau-181 in type 2 diabetes mellitus patients with different HbA1c levels

Gao, Y., Sui, C., Chen, B., Xin, H., Che, Y., Zhang, X., Wang, N., Wang, Y., & Liang, C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1202374 · Cited by 15

Rebuilding insight into the pathophysiology of Alzheimer's disease through new blood-brain barrier models

Matsuo, K., & Nishihara, H. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390978 · Cited by 14

Advance and Prospect of Positron Emission Tomography in Alzheimer’s disease research

Wang, Y., Liao, W., Wang, L., Li, J., Huang, D., Cheng, W., Tian, J., & Luan, P. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03081-2 · Cited by 13

Automated synthesis, preclinical toxicity, and radiation dosimetry of [18F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood-brain barrier

Toyohara, J., Sakata, M., Tago, T., Colabufo, N. A., & Luurtsema, G. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00674-6 · Cited by 13

Role of (Drug) Transporters in Imaging in Health and Disease

Stieger, B., Unadkat, J. D., Prasad, B., Langer, O., & Gali, H. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059873 · Cited by 13

Data-independent acquisition proteomic analysis of the brain microvasculature in Alzheimer’s disease identifies major pathways of dysfunction and upregulation of cytoprotective responses

Erickson, M. A., Johnson, R. S., Damodarasamy, M., MacCoss, M. J., Keene, C. D., Banks, W. A., & Reed, M. J. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00581-1 · Cited by 12

Modeling the Blood–Brain Barrier to Understand Drug Delivery in Alzheimer’s Disease

Wasielewska, J. M., Chaves, J., White, A. R., & Oikari, L. E. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch7 · Cited by 13

Increasing Intracellular Levels of Iron with Ferric Ammonium Citrate Leads to Reduced P-glycoprotein Expression in Human Immortalised Brain Microvascular Endothelial Cells

Newman, S. A., Pan, Y., Short, J. L., & Nicolazzo, J. A. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03006-y · Cited by 13

Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4

Hafey, M. J., Aleksunes, L. M., Bridges, C. C., Brouwer, K. R., Chien, H., Leslie, E. M., Hu, S., Li, Y., Shen, J., Sparreboom, A., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2638 · Cited by 14

Mamma Mia, P‐glycoprotein binds again

Callaghan, R., Gelissen, I. C., George, A. M., & Hartz, A. M. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.13951 · Cited by 12

Altered peripheral factors affecting the absorption, distribution, metabolism, and excretion of oral medicines in Alzheimer’s disease

Waller, E. S., Yardeny, B. J., Fong, W. Y., Gan, X. Y., Jimenez, S. V., Pan, Y., Abasszade, J. H., & Nicolazzo, J. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114282 · Cited by 12

Synthesis and Evaluation of New Fluorine-18 Labeled Verapamil Analogs To Investigate the Function of P-Glycoprotein in the Blood–Brain Barrier

Raaphorst, R. M., Luurtsema, G., Schuit, R. C., Kooijman, E. J. M., Elsinga, P. H., Lammertsma, A. A., & Windhorst, A. D. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00086 · Cited by 12

Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome

Chaturvedi, S., Rashid, M., Malik, M. Y., Agarwal, A. K., Singh, S. K., Gayen, J. R., & Wahajuddin, M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.007 · Cited by 11

The endocrine pancreas of old obesehyperglycemic mice.

Westman, S. (1968) · PubMed · Cited by 11

P-glycoprotein and Alzheimer’s Disease: Threats and Opportunities

Asante, J., & Barger, S. W. (2025) · ASN NEURO · doi:10.1080/17590914.2025.2495632 · Cited by 11

Blood–brain barrier disruption in dementia: Nano‐solutions as new treatment options

Cooper, C. G., Kafetzis, K. N., Patabendige, A., & Tagalakis, A. D. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16229 · Cited by 11

Vascular models of Alzheimer's disease: An overview of recent in vitro models of the blood-brain barrier

Takeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 11

Quantitation of multiple injection dynamic PET scans: an investigation of the benefits of pooling data from separate scans when mapping kinetics

Gu, F., O’Sullivan, F., Muzi, M., & Mankoff, D. A. (2021) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac0683 · Cited by 10

Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model

Wanek, T., Zoufal, V., Brackhan, M., Krohn, M., Mairinger, S., Filip, T., Sauberer, M., Stanek, J., Pekar, T., Pahnke, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218245 · Cited by 9

Alzheimer's disease brain endothelial-like cells reveal differential drug transporter expression and modulation by potentially therapeutic focused ultrasound

Chaves, J. C. S., Wasielewska, J. M., Cuní‐López, C., Rantanen, L. M., Lee, S., Koıstınaho, J., White, A. R., & Oikari, L. E. (2023) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.009 · Cited by 10

Unravelling the Alzheimer's pathogenesis: Molecular and cellular pathways to neurodegeneration and therapeutic targets

Chauhan, P., Wadhwa, K., & Singh, G. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156109 · Cited by 12

First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood–brain barrier

Toyohara, J., Sakata, M., Ishibashi, K., Mossel, P., Imai, M., Wagatsuma, K., Tago, T., Imabayashi, E., Colabufo, N. A., Luurtsema, G., et al. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01666-9 · Cited by 9

Glucocorticoids modify effects of TGF-β1 on multidrug resistance in the fetal blood-brain barrier

Baello, S., Iqbal, M., Kearney, S., Kuthiala, S., Bloise, E., Gibb, W., & Matthews, S. G. (2016) · Growth Factors · doi:10.3109/08977194.2016.1162163 · Cited by 9

The 3D Brain Unit Network Model to Study Spatial Brain Drug Exposure under Healthy and Pathological Conditions

Vendel, E., Rottschäfer, V., & de Lange, E. C. M. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-2760-y · Cited by 8

Human isogenic cells of the neurovascular unit exert transcriptomic cell type-specific effects on a blood-brain barrier in vitro model of late-onset Alzheimer disease

Haferkamp, U., Hartmann, C., Abid, C. L., Brachner, A., Höchner, A., Gerhartl, A., Harwardt, B., Leckzik, S., Leu, J., Metzger, M., et al. (2023) · Fluids and Barriers of the CNS · doi:10.1186/s12987-023-00471-y · Cited by 12

Impact of Cytochrome Induction or Inhibition on the Plasma and Brain Kinetics of [11C]metoclopramide, a PET Probe for P-Glycoprotein Function at the Blood-Brain Barrier

Breuil, L., Ziani, N., Leterrier, S., Hugon, G., Caillé, F., Bouilleret, V., Truillet, C., Goislard, M., Biali, M. E., Bauer, M., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122650 · Cited by 8

Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches

Loeffler, D. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1368200 · Cited by 10

Imagerie TEP pour l’étude des répercussions fonctionnelles de la P-glycoprotéine en neuropharmacocinétique

Marie, S., & Tournier, N. (2020) · Therapies · doi:10.1016/j.therap.2020.02.018 · Cited by 7

(R)-[11C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function

Toyohara, J., Okamoto, M., Aramaki, H., Zaitsu, Y., Shimizu, I., & Ishiwata, K. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.09.001 · Cited by 7

Synthesis and preliminary preclinical evaluation of fluorine-18 labelled isatin-4-(4-methoxyphenyl)-3-thiosemicarbazone ([18F]4FIMPTC) as a novel PET tracer of P-glycoprotein expression

Verbeek, J., Eriksson, J., Syvänen, S., Huisman, M. C., Schuit, R. C., Molthoff, C. F. M., Voskuyl, R. A., de Lange, E. C. M., Lammertsma, A. A., & Windhorst, A. D. (2018) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-018-0046-z · Cited by 7

One-health approach to canine cognitive decline: Dogs Overcoming Geriatric Memory and Aging Initiative for early detection of cognitive decline

Hunter, R. P., Ehrenzweig, J., Hainsworth, A. H., Crawford, A. H., Dagan, A., Sage, J., & Araujo, J. A. (2023) · American Journal of Veterinary Research · doi:10.2460/ajvr.23.02.0032 · Cited by 6

Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB

Heeman, F., Hendriks, J., Alves, I. L., Tolboom, N., van Berckel, B. N. M., Yaqub, M. M., & Lammertsma, A. A. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01606-z · Cited by 6

Recent advances in drug transporter sciences: highlights from the year 2020

Chothe, P. P., Nakakariya, M., Rotter, C. J., Sandoval, P., & Tohyama, K. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1963270 · Cited by 6

[ 11 C]metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier

Mairinger, S., Leterrier, S., Filip, T., Löbsch, M., Pahnke, J., Hernández-Lozano, I., Stanek, J., Tournier, N., Zeitlinger, M. A., Hacker, M., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231202336 · Cited by 6

Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer’s diseasePreprint

Sekhar, G. N., Fleckney, A. L., Boyanova, S. T., Rupawala, H., Lo, R., Wang, H., Farag, D. B., Rahman, K. M., Broadstock, M., Reeves, S., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/582387 · Cited by 6

Single-cell multi-region dissection of brain vasculature in Alzheimer’s DiseasePreprint

Sun, N., Akay, L. A., Murdock, M. H., Park, Y., Bubnys, A., Galani, K., Mathys, H., Jiang, X., Ng, A. P., Bennett, D. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.09.479797 · Cited by 6

A role of P-glycoprotein in neurology

Chernykh, I. V., Shchulkin, A. V., Yakusheva, E. N., & Popova, N. M. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20171171167-71 · Cited by 5

An In Vitro Model of the Blood–Brain Barrier to Study Alzheimer’s Disease: The Role of β-Amyloid and Its Influence on PBMC Infiltration

Spampinato, S. F., Takeshita, Y., & Obermeier, B. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2289-6_20 · Cited by 5

Blood-Brain Barrier Dysfunction in the Detrimental Brain Function

González‐Candia, A., Rogers, N. K., & Castillo, R. L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.94572 · Cited by 5

Mind over microplastics — what we still don’t know

Aschner, M. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01097-4 · Cited by 4

Modeling neurovascular dysfunction in Alzheimer’s disease using an isogenic brain-chip model

Shen, A. N., Matazel, K. S., Gill, W. D., Ewart, L. C., Daughters, R. S., & Rosas-Hernández, H. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00708-y · Cited by 5

Histone and non-histone (de)acetylation impact on the blood-brain barrier

Melo, M., Fortuna, A. C., Laranjinha, J. A. N., & Bicker, J. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00763-z · Cited by 5

Comprehensive profiling of traditional herbomineral formulation Manasamitra vatakam in rat brain following oral administration and in-silico screening of the identified compound for anti-Alzheimer's activity

Nair, A. C., Benny, S., Aneesh, T. P., Sudheesh, M. S., & Lakshmi, P. K. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119024 · Cited by 5

RIPK1 expression and inhibition in tauopathies: implications for neuroinflammation and neuroprotection

Silva-Llanes, I., Madruga, E. L., Martı́nez, A., & Lastres‐Becker, I. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1530809 · Cited by 5

Impact of reduced P‐glycoprotein function on digoxin concentrations in patients with dementia

Ali, I., Guidone, D., Nicolazzo, J. A., & Brouwer, K. L. R. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14049 · Cited by 4

Effect of Apolipoprotein E isoforms on the Abundance and Function of P-glycoprotein in Human Brain Microvascular Endothelial Cells

Kreutzer, E., Short, J. L., & Nicolazzo, J. A. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03731-0 · Cited by 4

Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide

Bauer, M., Barna, S., Blaickner, M., Prosenz, K., Bamminger, K., Pichler, V., Tournier, N., Hacker, M., Zeitlinger, M. A., Karanikas, G., et al. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01582-4 · Cited by 3

Parametric Imaging of P-Glycoprotein Function at the Blood–Brain Barrier Using kE,brain-maps Generated from [11C]Metoclopramide PET Data in Rats, Nonhuman Primates and Humans

Breuil, L., Biali, M. E., Vodovar, D., Marie, S., Auvity, S., Bauer, M., Goutal, S., Rodrigo, S., Langer, O., & Tournier, N. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01864-z · Cited by 3

Alzheimer’s disease brain endothelial-like cells reveal differential drug transporter expression and modulation by potentially therapeutic focused ultrasoundPreprint

Chaves, J. C. S., Wasielewska, J. M., Cuní‐López, C., Rantanen, L. M., Lee, S., Koıstınaho, J., White, A. R., & Oikari, L. E. (2023) · Research Square · doi:10.21203/rs.3.rs-2605800/v1 · Cited by 3

Decoding Blood-Brain Barrier Dysfunction in Alzheimer's Disease: Innovations and Challenges in Multimodal MRI and PET Imaging Biomarkers.

Yin, H., Lu, Z., Deng, Y., Tian, X., & Gong, Q. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102952 · Cited by 6

Brain health across the lifespan and the impact of nutrition, exercise, microbiota, and sleep

Shin, A. C., Haque, Z. F., Galyean, S., Hefner, M., Esmaeili, M., Lawrence, J. J., & Watkins, B. A. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103245 · Cited by 3

The Blook-Brain Barrier in Health and Disease

Mayhan, W. G., & Arrick, D. M. (2016) · Colloquium Series on Integrated Systems Physiology From Molecule to Function · doi:10.4199/c00148ed1v01y201612isp072 · Cited by 2

Blood–Brain Barrier in Alzheimer's Disease

Brito, M. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813146-6.00025-4 · Cited by 3

Zinc‐Based Nanocomposites for Alzheimer's Therapy: Restoring Metal Homeostasis and Inhibiting Neurotoxic Protein Aggregation

Yadav, S., Pandey, S. K., & Awasthi, S. (2026) · Advanced Therapeutics · doi:10.1002/adtp.202500576 · Cited by 1

Progress and challenges in drug delivery for the treatment of Alzheimer’s disease

Haghighi, F. H., Xie, J., Ebert, E., & Siahaan, T. J. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2663114 · Cited by 1

PET in Neurological and Psychiatric Disorders: Technologic Advances and Clinical Applications

Matusch, A., & Kroll, T. (2016) · Springer eBooks · doi:10.1007/978-3-319-40070-9_20 · Cited by 1

In Vitro Blood-Brain Barrier Functional Assays in a Human iPSC-Based Model

Neal, E., Shi, Y., & Lippmann, E. (2019) · Neuromethods · doi:10.1007/978-1-4939-9228-7_1 · Cited by 1

Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs

Pang, K. S., Peng, H., Li, B. P., Wen, B., Noh, K., Xia, R., Toscan, A., Serson, S., Fraser, P. E., Tirona, R. G., et al. (2024) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2386 · Cited by 1

PET Imaging of ABC Transporters at the Blood–Brain Barrier

Langer, O. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679430.ch8 · Cited by 1

Regulation of efflux transporter expression and function in neural injury and inflammation

Gibson, C. (2015) · doi:10.7282/t3377bf2

The Blood-Brain Barrier in Health and Disease

Mayhan, W. G., & Arrick, D. M. (2016)

Regulation of ABCB1 expression and activity in porcine brain endothelial cells

Vergara, P. (2016) · Research Explorer (The University of Manchester)

PET Imaging in Cancer Clinical Trials

Mankoff, D. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816386-3.00082-x

New strategies for imaging brain-related therapy

Arif, W. M. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.261538587

Analysis of transporter activity in an Alzheimer’s disease blood-brain barrier cell model

Chaves, J. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.248279

Neurodegenerative diseases and dementia: the role of blood-brain barrier dysfunction (based on recent evidence)

Levin, O. S., & Гехаева, З. К. (2025) · The Clinician · doi:10.17650/1818-8338-2025-19-1-k744

Alzheimer’s disease PSEN-2 N141I mutation reveals altered and shear-sensitive brain endothelial cell-like phenotype in human iPSC-derived models

Takeuchi, L. E., Lam, J., & Simmons, C. A. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02152-3

Additional file 7 of Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615655

Additional file 1 of Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615637

Additional file 6 of Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615652

Additional file 2 of Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615640

Additional file 5 of Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615649

Additional file 3 of Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615643

Additional file 4 of Effects of whole-brain radiation therapy on the blood–brain barrier in immunocompetent and immunocompromised mouse models

Blethen, K. E., Sprowls, S. A., Arsiwala, T. A., Wolford, C. P., Panchal, D. M., Fladeland, R. A., Glass, M. J., Dykstra, L. P., Kielkowski, B. N., Blackburn, J. R., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22615646

Ketogenic diet impacts Blood-Brain Barrier physiology : implications for Alzheimers's disease

Corsi, M. (2018) · theses.fr (ABES) · doi:10.70675/36cd4c36z2faaz4535zaafdz8f54069c5015

Marqueurs périphériques de l'inflammation et déclin cognitif au cours de la maladie d'Alzheimer

Julian, A. (2018) · theses.fr (ABES) · doi:10.70675/0f58e0a1z28d9z40b7z886fz752caf42c261

Putative Modulation of OATP1A2 and P-gp Expression at the Blood–Brain Barrier by Nrf2–PXR: An Associative Hypothesis for Amyloid-β Transport in Alzheimer’s Disease

Li, L., Zhang, Y., Li, S., Zhao, M., Hu, W., Xiao, Y., & Wen, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167264

Cerebral Intramural Cells: A Missing Cellular Link Between Vascular Aging and Alzheimer’s Disease

Arbănași, E. M., Arbănași, E. M., Boghițoiu, T., Cărare, S. A., Cordoș, B. A., Braysh, K., Suciu, N., Chinezu, L., Manu, D. R., Montagne, A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167353

UPS-mediated P-glycoprotein regulation in Alzheimer’s disease: pharmacological implications for the amyloid pathology

Joshi, A., Salunkhe, J., & Ugale, V. G. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12722-w

P4‐176: Activity of P‐glycoprotein, an ABC efflux transporter at the blood‐brain barrier, is compromised in Alzheimer's disease

Deo, A. K., Soo Borson, B., Link, J. M., Eary, J. F., Richards, T. L., Mankoff, D. A., Hsiao, P., Minoshima, S., Maravilla, K., & Unadkat, J. D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1880

Blood–brain barrier P-glycoprotein function in Alzheimer's disease

van Assema, D. M. E., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., Windhorst, A. D., Comans, E. F. I., Hoetjes, N. J., Tolboom, N., Langer, O., et al. (2012) · Brain · doi:10.1093/brain/awr298 · Cited by 318

O1‐07‐04: Blood‐brain barrier p‐glycoprotein function in Alzheimer's disease

van Assema, D. M. E., Scheltens, P., van Berckel, B. N. M., van der Flier, W. M., Tolboom, N., Lammertsma, A. A., Windhorst, A. D., Müller, M., Lubberink, M., Bauer, M., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.275 · Cited by 2

A JOURNAL OF NEUROLOGY Blood–brain barrier P-glycoprotein

van Berckel, B. N. M., & Alzheimer Centre (2016)

Abundance of P‐Glycoprotein and Other Drug Transporters at the Human Blood‐Brain Barrier in Alzheimer’s Disease: A Quantitative Targeted Proteomic Study

Storelli, F., Billington, S. F., Kumar, A. R., & Unadkat, J. D. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2035 · Cited by 59